508 Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?

Cooper, Amanda; Parmar, Abhishek D.; Hall, Bruce L.; Katz, Matthew H.; Fleming, Jason B.; Aloia, Thomas A.; Riall, Taylor S.; Pitt, Henry A.

doi:10.1016/s0016-5085(14)63697-0

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior studies have documented improved postoperative outcomes for patients undergoing minimally invasive vs. open distal pancreatectomy. 4,8,15 However, few analyses have focused on a minimally invasive DP approach specifically for the treatment of PDAC. 2,5,[7][8][9][10]17,18 This study expands on the minimal data which have been published.…”

Section: Discussionmentioning

confidence: 99%

“…The sampling strategy, data abstraction procedures, variables collected and structure have been published. [11][12][13][14][15][16] One hundred and thirty-six preoperative (patient characteristics), intraoperative (processes of care) and postoperative (adverse outcomes) variables were prospectively collected by trained, certified Surgical Clinical Reviewers in the ACS-NSQIP. Patients younger than 18 years of age were excluded.…”

Section: Source Of Data: Acs-nsqipmentioning

confidence: 99%

See 1 more Smart Citation

Reduced morbidity with minimally invasive distal pancreatectomy for pancreatic adenocarcinoma

Plotkin

Ceppa

Zarzaur

et al. 2017

HPB

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Source Of Data: Acs-nsqipmentioning

confidence: 99%

Reduced morbidity with minimally invasive distal pancreatectomy for pancreatic adenocarcinoma

Plotkin

Ceppa

Zarzaur

et al. 2017

HPB

Self Cite

View full text Add to dashboard Cite

show abstract

Quantifying the Burden of Complications Following Total Pancreatectomy Using the Postoperative Morbidity Index: A Multi-Institutional Perspective

Datta

Lewis

Strasberg

et al. 2015

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer

Dimou

Sineshaw

Parmar

et al. 2016

Journal of Gastrointestinal Surgery

Self Cite

View full text Add to dashboard Cite

INTRODUCTION Pancreatic cancer is considered a systemic disease at presentation. Therefore, multimodality therapy with surgical resection and chemotherapy is the standard of care for locoregional disease. We described treatment patterns and time trends with regards to age and treatment center in the receipt of multimodality therapy. METHODS We used the National Cancer Data Base to identify patients ≥18 years old with stage I and II pancreatic adenocarcinoma. Treatment was defined as no treatment, resection only, chemotherapy only, or multimodality therapy, which consisted of both chemotherapy (neoadjuvant or adjuvant) and resection. Trends in the receipt and type of treatment were compared. RESULTS Of 39,441 patients, 22.8% of patients received no treatment, 18.5% received chemotherapy only, 23.0% underwent surgical resection alone, and 35.8% of patients received multimodality therapy. Receipt of multimodality therapy increased from 31.3% in 2004 to 37.9% in 2011 (p<0.0001). Patients >55 years were less likely to receive multimodality therapy (56–64 years: OR 0.83, 95% CI 0.78–0.89; 65–75: OR 0.60, 95% CI 0.55–0.65; ≥76: OR 0.17, 95% CI 0.16–0.19 compared to patients 18–55). Compared to community hospitals, patients treated at an NCI-designated center were more likely to receive multimodality therapy (OR 1.62, 95% CI 1.46–1.81) and, if they received multimodality therapy, delivery of chemotherapy in the neoadjuvant compared to adjuvant setting (OR 2.82, 95% CI 2.00–3.98). CONCLUSION Despite increased use of multimodality therapy, it remains underutilized in all patients and especially in older patients. Receipt of multimodality therapy and neoadjuvant therapy are highly dependent on treatment at NCI-designated cancer centers.

show abstract

508 Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?

Cited by 4 publications

References 17 publications

Reduced morbidity with minimally invasive distal pancreatectomy for pancreatic adenocarcinoma

Reduced morbidity with minimally invasive distal pancreatectomy for pancreatic adenocarcinoma

Quantifying the Burden of Complications Following Total Pancreatectomy Using the Postoperative Morbidity Index: A Multi-Institutional Perspective

Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer

Contact Info

Product

Resources

About